Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Sonoma Pharmaceuticals (SNOA) Accumulated Depreciation & Amortization (2017 - 2025)

Sonoma Pharmaceuticals has reported Accumulated Depreciation & Amortization over the past 14 years, most recently at $138000.0 for Q1 2025.

  • For Q1 2025, Accumulated Depreciation & Amortization fell 21.59% year-over-year to $138000.0; the TTM value through Mar 2025 reached $138000.0, down 21.59%, while the annual FY2025 figure was $138000.0, 21.59% down from the prior year.
  • Accumulated Depreciation & Amortization for Q1 2025 was $138000.0 at Sonoma Pharmaceuticals, down from $176000.0 in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $227000.0 in Q1 2021 and troughed at $125000.0 in Q1 2023.
  • A 5-year average of $170400.0 and a median of $176000.0 in 2024 define the central range for Accumulated Depreciation & Amortization.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: crashed 32.8% in 2023 and later skyrocketed 40.8% in 2024.
  • Year by year, Accumulated Depreciation & Amortization stood at $227000.0 in 2021, then dropped by 18.06% to $186000.0 in 2022, then crashed by 32.8% to $125000.0 in 2023, then surged by 40.8% to $176000.0 in 2024, then decreased by 21.59% to $138000.0 in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for SNOA at $138000.0 in Q1 2025, $176000.0 in Q1 2024, and $125000.0 in Q1 2023.